8-K
GoodRx Holdings, Inc. (GDRX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 10, 2021
GoodRx Holdings, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 001-39549 | 47-5104396 |
|---|---|---|
| (State or Other Jurisdiction<br> <br>of Incorporation) | (Commission<br> <br>File Number) | (IRS Employer<br> <br>Identification No.) |
2701 Olympic Boulevard
Santa Monica, CA 90404
(Address of Principal Executive Offices) (Zip Code)
(855) 268-2822
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> <br>Symbols | Name of each exchange<br> <br>on which registered |
|---|---|---|
| Class A Common Stock, $0.0001 par value per share | GDRX | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
|---|
On November 10, 2021, GoodRx Holdings, Inc. (the “Company”), announced the Company’s financial results for the three and nine months ended September 30, 2021. The full text of the press release and letter to shareholders issued in connection with the announcement are furnished as Exhibits 99.1 and 99.2, respectively, to this report.
The information in Item 2.02 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
|---|---|
| (d) | Exhibits. |
| --- | --- |
| 99.1* | Press Release, dated November 10, 2021. |
| --- | --- |
| 99.2* | Letter to Shareholders, dated November 10, 2021. |
| 104 | Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document. |
| * | Furnished herewith. |
| --- | --- |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GOODRX HOLDINGS, INC. | |
|---|---|
| By: | /s/ Karsten Voermann |
| Name: | Karsten Voermann |
| Title: | Chief Financial Officer |
Date: November 10, 2021
EX-99.1
Exhibit 99.1
GoodRx Releases Third Quarter 2021 Financial Results
SANTA MONICA, Calif. November 10, 2021 – GoodRx Holdings, Inc. (Nasdaq: GDRX), America’s digital resource for healthcare, has released its third quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com.
GoodRx management will host a conference call and webcast today at 2:00 pm. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company’s business outlook.
Third Quarter 2021 Results Conference Call
| Date: | Wednesday, November 10, 2021 |
|---|---|
| Time: | 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time |
| Webcast: | https://investors.goodrx.com (live and replay) |
| Dial-in number: | (833) 614-1447 |
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is America’s digital resource for healthcare. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save $35 billion and are one of the most downloaded medical apps over the past decade.
Investor Contact
GoodRx
Whitney Notaro
wnotaro@goodrx.com
Press Contact
GoodRx
Lauren Casparis
lcasparis@goodrx.com
EX-99.2
Exhibit 99.2
Q3 2021 Letter to Shareholders November 10, 2021
GoodRx helps Americans get the healthcare they need at a price they can afford. I use GoodRx myself because I have a high deductible insurance plan. Paying $100 for a medication is ridiculous even for a doctor. Alysia Ogburia, MD Primary Care Physician GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 2
Perspectives from Doug and Trevor This letter marks the 10th anniversary of GoodRx. Over the past 10 years, we've worked hard to create ways to help millions of Americans access affordable care. Today, GoodRx supports patients across each stage of their healthcare journey, delivering savings, trusted information, and access to care to Americans. While many companies talk about making the world a better place, making a difference is what we do. GoodRx has saved Americans $35 billion on their prescriptions compared to the pharmacy cash price. Consumer savings have increased to 80%,1 and we beat insurance over 50% of the time.2 In addition, we continue to increase access to brand drugs through our pharma manufacturer relationships. For many of our users, GoodRx is not just about saving money. It's about whether they will be able to buy their medication, or their children's medication, or not. In fact, we estimate that we have helped patients obtain at least 80 million prescriptions they otherwise may not have been able to afford.3 We believe our impact has never been greater and, with yet another quarter of record results, our business has never been stronger. Because of GoodRx, millions of Americans can now afford medications and care. Because of GoodRx, millions of Americans are more informed and better prepared to make healthcare decisions, from diagnosis to care delivery. Because of GoodRx, millions of patients can navigate the confusing world of healthcare knowing they have a trusted advocate by their side. We continue building our broad and deep competitive moat which is rooted in the trust we've established with patients, physicians, and companies across all of healthcare. Patients trust us, and our consumer NPS of 904 is a testament to the important role we play in their care. Physicians and healthcare professionals trust us, with over 2 million prescribers that have a patient that has used GoodRx and a very high provider NPS of 90.5 Companies look to us as a way to introduce products and services, and provide savings to our large and growing audience. We work with more PBMs and pharmacies than ever and have continued to strengthen these relationships. As we grow, we believe our advantages in scale and data increase, allowing us to drive deeper consumer savings and provide richer engagement. Our offerings - including subscriptions, pharma manufacturer solutions, and telehealth - allow us to reach more consumers at different points of need along their healthcare journey, from diagnosis to treatment to care. A decade later, we still start every new project with the ultimate goal of helping more people. In September, we launched GoodRx Health, a new consumer resource for clear, research-based answers to vital health questions. Unlike other consumer health destinations, GoodRx Health tackles the tough stuff, with an expert team of doctors, pharmacists, and editorial experts who dig deep to provide concise, actionable knowledge. We value quality over quantity, and believe our visitors will appreciate the difference. GoodRx Health builds on GoodRx's decade of experience as America's leading resource for healthcare savings. Our editorial team has already published thousands of stories that have earned top rank on competitive queries about topics from erectile dysfunction to COVID-19 vaccines. We're now planning to expand upon this foundation to include subjects from health insurance to women's health, and weight loss to mental health. GoodRx Health also includes thousands of engaging, expert videos from HealthiNation, which we acquired earlier this year. GoodRx Health creates opportunities to continue to expand our Pharma Manufacturer Solutions offering as well and address the $30 billion spent annually on pharma marketing. We are giving manufacturers more ways to reach large, high-intent audiences with their medications and products, with the goal of building a robust win-win business. In the year since our IPO, we have launched new resources, features, and services to provide more value to our consumers. We've acquired new capabilities to help grow the scale of our business, expanded and deepened pharmacy and PBM relationships, and developed strategic partnerships with enterprise-level companies that extend the reach of our prescription-related offerings. This has all been fueled by the passion of our team and unrelenting dedication to our mission. Despite our success, Americans still face rising costs, decreasing life expectancy, and poorer health outcomes. We feel a tremendous sense of urgency to find more ways to help more people, and we believe that our efforts can help reverse those trends. In the coming years, we see more opportunities to help Americans fill more gaps in their healthcare journey including navigating insurance as their trusted advocate, further personalizing the GoodRx user experience, and extending our marketplace. We believe that we are just getting started and have barely scratched the surface of the opportunity to transform healthcare in the U.S. We won't rest until all Americans have access to affordable, high-quality, and convenient healthcare. Doug Hirsch Co-Founders & Co-CEOs, GoodRx Trevor Bezdek 1 Based off of the pharmacy cash price. 2 Based on a GoodRx study, The GoodRx Effect. In 2020, over 55% of prescriptions lled using GoodRx (including our Gold and Kroger membership savings programs) were cheaper than the average commercial insurance copays for the 100 most purchased medications, based on industry data. When GoodRx users paid less than average commercial insurance copays, they saved on average 52% off average commercial insurance copays in 2020. 3 Internal estimate. 4 Consumer NPS based on July 2021 survey on the GoodRx website. 5 Provider NPS based on September 2021 survey on the GoodRx website. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 3
Q3 2021 Highlights Net Adjusted Adjusted Revenue Loss EBITDA2 Net Income2 $195.1M ($18.1M)* $61.8M $39.7M +39% YOY (9.3%) Margin1 31.7% Margin1 20.3% Margin1 * Q3 ‘21 Net Loss was impacted by $19.2M of income tax expense and $40.0M of stock-based compensation expense, $20.1M of which related to the non-recurring co-CEOs’ awards made in connection with the IPO. Exited the quarter with nearly Monthly Active Consumers3 8M Consumers of our prescription-related offerings Q3 ‘21 6.4M +31% YOY Q3 ‘20 4.9M Subscription Plans4 MACs + subscription user count Q3 ‘21 1,129K +68% YOY Q3 ‘20 673K Financial Data (dollars in millions) Q3 2021 Q3 2020 Change Revenue $195.1 $140.5 39% Net Loss ($18.1) ($50.0) NM Adjusted Net Income2 $39.7 $35.6 11% Adjusted EBITDA2 $61.8 $53.2 16% Adjusted EBITDA Margin2 31.7% 37.8% (610 bps) Cash Provided by Operating Activities $48.6 $32.7 49% 1 Net Margin, Adjusted EBITDA Margin, and Adjusted Net Margin represent Net Loss, Adjusted EBITDA, and Adjusted Net Income divided by Revenue, respectively. 2 Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures. 3 Monthly Active Consumers (MACs) represent the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. Beginning in the fourth quarter of 2020, our Monthly Active Consumers number includes consumers we acquired through the acquisition of Scriptcycle in August 2020. RxSaver (acquired in April 2021) Monthly Active Consumers have been included as of the beginning of the third quarter of 2021 and are estimated due to incomplete consumer information. Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who used our telehealth offerings. When presented for a period longer than a month, Monthly Active Consumers is averaged over the calendar months in such period. 4 Represents the ending subscription plan balance across both of our subscription offerings, GoodRx Gold and Kroger Savings Club. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 4
GoodRx Helps More Consumers at More Stages of Their Healthcare Journey Than Ever We have substantially extended our platform to address more of the consumer healthcare journey HealthiNation GoodRx Care Research & Prevention Diagnosis CONSUMER GoodRx Health HEALTHCARE JOURNEY Telehealth Marketplace Treatment & Adherence Rx Refill Prescription Reminders & Savings Dashboard Pharma Mail Manufacturer Delivery Solutions Subscription Programs Key milestones in the year since our IPO: Research & Prevention Diagnosis Treatment & Adherence Acquired Rebranded & Acquired Expanded Nationwide Launched Launched Launched GoHealth / Insurance, Integrated Copay GoHealth / Insurance Card, integrated offerings with Boehringer Ingelheim and Sanofi COVID Vaccine Guide & Wallet Increased Expanded Care cross-sell to 65% Partnered DoorDash, USAA, Fetch Rewards GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 5
Business Updates We delivered record revenue and record users in the third quarter. We added new features and improved the user experience, increased our scale and customer penetration in pharma manufacturer solutions, and continued to deliver on our mission to help Americans get the healthcare they need, reaching $35 billion of cumulative savings. We also launched GoodRx Health, which is a new, potentially TAM-expanding focus area for us that we’re particularly excited about. GoodRx Health is our next-generation online health resource where doctors, pharmacists, and editorial experts provide authoritative answers to thousands of crucial health questions. We believe this new resource will deliver more insights to consumers throughout their healthcare journey, increase our top of funnel traffic, and create new monetization opportunities. This is a key milestone for us. The demand for health and wellness information in the U.S. is massive. Millions of users already come to GoodRx every month looking to increase their knowledge of health topics. By adding GoodRx Health to our portfolio of resources, we aim to help more Americans at every stage of their healthcare journey - from diagnosis to treatment and care. GoodRx Health allows us to reach more people in more ways through content that empowers them to be advocates for their own health across a wide range of healthcare decisions. GoodRx Health’s content focuses on four main areas: “ Health Knowledge. A deep dive into medical research and scientific literature to address common health questions reviewed by physicians, pharmacists, psychologists, psychiatrists, or veterinarians, depending on the subject matter. “ Financial Guidance. Expert resources around cost, savings and insurance coverage to help consumers make smart decisions about their money and their health. “ Drug FAQs. Straight answers on basic medication questions reviewed by pharmacists. “ Trustworthy Research. Timely and original research around drug prices, fill trends, and the U.S. healthcare system so consumers can stay up-to-date on the latest information. Introducing GoodRx Health. The health answers you need. GoodRx Answers. Personalized Video Explainers. Health Wizards. Thousands of articles with Newsletters. Easy-to-understand guidance Custom tools using data to research-backed answers to Information on the conditions from healthcare experts. help navigate tough choices. health questions. and topics users care about, delivered every week. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 6
GoodRx Health is powered by a dedicated editorial team, including leading doctors, pharmacists, and editorial experts, and taps into current medical perspectives with the goal of creating the most trusted and most useful health information resource on the internet. We deliver this information in unique formats to help ensure consumers can quickly find the health information they need. We do so through GoodRx Answers, Health Assistants, Health Debunked, and Video Explainers. GoodRx Health is key to our content strategy and is expected to further strengthen our relationships with consumers and providers, create additional M&A opportunities, and support the growth of our current and future offerings by increasing our top of funnel trafc, especially for pharma manufacturer solutions. We believe there's a tremendous opportunity to leverage GoodRx Health content, as well as content from HealthiNation, which we acquired earlier this year, to help providers and consumers navigate the complex world of brand medications and increase awareness, access, and adherence. By adding GoodRx Health to our portfolio of resources, we are furthering our goal of filling more gaps by delivering strong savings, trusted information, and access to care for all Americans. Content-driven top of funnel expansion helps fuel consumer acquisition and engagement and further propels pharma manufacturer solutions growth. 350+ Health conditions covered 2,500+ Videos in GoodRx library Opportunities across the GoodRx platform Consumer insights. Educate users and build pre-transaction readiness. Conversion to MACs and subscribers. Reach consumers interested in healthcare research with price discovery and discounts. Broader audiences for pharma manufacturers. Enable bigger, broader awareness opportunities within the GoodRx ecosystem for new and existing partners. Cross-selling to other GoodRx products. Provide additional telehealth cross-sell opportunities. Enables new M&A opportunities. Broader consumer and provider audiences and needs create new M&A opportunities. During the quarter we also became the exclusive prescription savings provider for Fetch Rewards, the fastest-growing consumer loyalty and shopper rewards app in the U.S., further increasing the reach of our Prescription Transactions offering. Fetch Rewards' over 10 million active shoppers can now find GoodRx prescription savings directly in the Fetch Rewards app, allowing them to seamlessly access GoodRx discounts on medications at over 70,000 pharmacies nationwide. We're excited to partner with Fetch Rewards and offer its millions of users a way to save on prescription medication, and we see opportunities to expand this partnership in the years to come. We also entered into an exciting agreement with CoverMyMeds, to further our Pharma Manufacturer Solutions offering. This is a joint go-to-market effort to create custom prescription discounts for consumers supported by the pharma manufacturer. This opportunity includes joint commercialization as well as integrated technology components to create a seamless experience for patients, providers, and pharmacies, that provides the patient tools and support most relevant to their specic journey to get on and stay on therapy. CoverMyMeds is a leader in biopharma-supported solutions for patient affordability and, as a leader in consumer affordability solutions, we see this as a natural partnership. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 7
Financials Prescription Transactions Revenue
Third quarter Prescription Transactions Revenue grew 25% year-over-year to $155.7 million, driven by a 31% year-over-year increase in MACs, partially offset by a lower contribution-per-consumer due to the acquisitions of Scriptcycle and RxSaver. We believe our prescription offering continued to be impacted by COVID-19 headwinds, as the undiagnosed condition backlog remains significant. (in millions) $155.7 $144.9 $131.3 $134.1 $123.0 $124.4 $109.5 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 Subscription Revenue1 (in millions) Third quarter Subscription Revenue grew 111% year-over-year $16.2 to $16.2 million, driven by a 68% increase in the number of $14.3 subscription plans across GoodRx Gold and Kroger Savings $12.0 Club, as well as a favorable change in subscription plan mix. $9.7 $7.7 $6.4 $5.6 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 Other Revenue1 (in millions) Third quarter Other Revenue grew 177% year-over-year to $23.2 $23.2 million, driven primarily by higher revenue from pharma manufacturers. Telehealth revenue grew year-over-year as well. $17.4 $12.5 $14.4 $8.4 $7.4 $4.8
Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 1 Beginning in Q2 2021, Subscription Revenue is disclosed separately from Other Revenue, which now primarily consists of revenue generated from our Pharma Manufacturer Solutions and Telehealth offerings. Prior period amounts have been recast to conform to the current period presentation.
GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 8
Net Income (Loss) (in millions) Third quarter Net Loss was $18.1 million, compared to a Net Loss of $50.0 million in the third quarter of 2020. The year-over-year change was driven primarily by a $65.1 million decrease in stock-based compensation expense and related payroll taxes, primarily related to the non-recurring Co-Chief Executive Officers’ awards made in connection with the IPO. This was partially offset by an increase to our tax provision, which was a $19.2 million expense in the third quarter of 2021 compared to a $17.9 million benefit in the comparable period last year. In addition, the change was also driven by business growth, partially offset by an increase in sales and marketing spend, as well as continued investments in product development and technology, and investments in our general and administrative infrastructure as we were operating as a public company for the full quarter of the 2021 period. Third quarter Net Margin was (9.3%) compared to (35.6%) last year, a 26.3 percentage point year-over-year improvement. Adjusted EBITDA Third quarter Adjusted EBITDA grew 16% to $61.8 million compared to $53.2 million in the third quarter of 2020. Adjusted EBITDA Margin was 31.7%, a 610 basis point year-over-year decrease. The margin decrease was driven by continued investments in product development and technology, an increase in sales and marketing spend, and investments in our general and administrative infrastructure as we began operating as a public company. (in millions) $27.3 $27.3 $31.1 $1.7 ($18.1) ($50.0) ($298.3) Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 (in millions) $61.8
$54.6 $51.9 $53.2 $51.0 $49.4 $49.1
Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 9
Adjusted Net Income Third quarter Adjusted Net Income grew 11% to $39.7 million compared to $35.6 million in the third quarter of 2020. (in millions) $39.7 $35.6 $35.1 $33.2 $32.3 $32.2 $31.8 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021 Adjusted Net Income is a non-GAAP financial measure and is presented for supplemental informational purposes only. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and a reconciliation to the most directly comparable GAAP measures. Net Cash Provided by Operating Activites Third quarter Net Cash Provided by Operating Activities was up 49% year-over-year to $48.6 million, made up of Net Loss of $18.1 million, adjusted primarily by stock-based compensation expense of $40.0 million and changes to our long-term deferred tax assets and tax receivables. The quarter-over-quarter increase was due primarily to business growth and changes in operating assets and liabilities, mainly driven by changes in accrued expenses and prepaid expenses and other assets.
The sequential decline in 2020 was due primarily to the timing of tax payments, the vast majority of which were made in the third and fourth quarters. These tax payments included payroll taxes related to the non-recurring Co-Chief Executive Officers’ equity awards and the exercise of stock options around and after our September 2020 IPO, as well as income tax payments as the extension, first, and second quarter payments were deferred to the third quarter. In addition, we prepaid certain marketing spend and other costs related to our operations as a public company, which further contributed to the decline in Q4. (in millions) $48.6 $45.6 $45.5 $38.2 $34.9 $32.7 $14.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2020 2021
GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 10
Guidance Our outlook for the fourth quarter and full year 2021 is as follows: Revenue Adjusted EBITDA Margin Revenue Adjusted EBITDA Margin Q4 2021 Guidance $212M to $222M Approx. 38% to 45% year-over-year growth Approx. 30% FY 2021 Guidance $744M to $754M Approx. 36% year-over-year growth Approx. 31% Adjusted EBITDA Margin is a non-GAAP financial measure and is presented for supplemental informational purposes only. We have not reconciled our Adjusted EBITDA Margin guidance to GAAP net income or loss margin, or Net Margin, because we do not provide guidance for GAAP Net Margin due to the uncertainty and potential variability of stock-based compensation expense and income taxes, which are reconciling items between Adjusted EBITDA Margin and GAAP Net Margin. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on GAAP Net Margin. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 11
Forward-Looking Statements This shareholder letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this shareholder letter that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future operations and financial results, the benefits to consumers or GoodRx of our agreements with partners, customers and other entities, the impact of GoodRx Health, underlying trends in our business, our market opportunity, the growth of our telehealth and manufacturer solutions businesses, the benefits of cross-selling products, competitiveness of our prices, especially in relation to insurance, the growth of our relationships with industry participants and partners, the anticipated impact of COVID-19 on our business, post-COVID-19 trends, our potential for growth, demand for our offerings, our strategic growth priorities and future offerings, future financial results, collaborations and partnerships with third parties, and our strategy. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our ability to achieve broad market education and change consumer purchasing habits; our ability to continue to attract, acquire and retain consumers in a cost-effective manner; our reliance on our prescription offering and ability to expand our offerings; changes in medication pricing and pricing structures; our inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infection disease, including the COVID-19 pandemic; the accuracy of our estimate of our total addressable market and other operational metrics; the development of the telehealth market; our ability to maintain and expand a network of skilled telehealth providers; risks related to negative media coverage; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform and brand; risks related to our material weaknesses in our internal control over financial reporting and any future material weaknesses; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to information technology and cyber-security; compliance with government regulation of the internet, e-commerce and data and other regulations; our ability to utilize our net operating loss carryforwards and certain other tax attributes; management's ability to manage our transition to being a public company; our ability to attract, develop, motivate and retain well-qualified employees; risks related to general economic factors, natural disasters or other unexpected events; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites; our reliance on third-party platforms to distribute our platform and offerings; our reliance on software as-a-service technologies from third parties; systems failures or other disruptions in the operations of these parties on which we depend; changes in consumer sentiment or laws, rules or regulations regarding tracking technologies and other privacy matters; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; risks related to fiuctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; as well as the other important factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this shareholder letter. Any such forward looking statements represent management's estimates as of the date of this shareholder letter. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. GoodRx Holdings, Inc. Q3 2021 Letter to Shareholders 12
Financial Statements
GoodRxHoldings, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| (in thousands, except par value) | December 31,2020 | ||||
|---|---|---|---|---|---|
| Assets | |||||
| Current assets | |||||
| Cash and cash equivalents | 912,023 | $ | 968,691 | ||
| Restricted cash | — | 2,900 | |||
| Accounts receivable, net | 98,511 | 68,729 | |||
| Prepaid expenses and other current assets | 41,006 | 46,048 | |||
| Total current assets | 1,051,540 | 1,086,368 | |||
| Property and equipment, net | 21,837 | 23,057 | |||
| Goodwill | 329,696 | 261,116 | |||
| Intangible assets, net | 94,077 | 36,919 | |||
| Capitalized software, net | 39,254 | 19,800 | |||
| Operating lease right-of-use<br>assets | 25,969 | 27,712 | |||
| Deferred tax assets, net | 45,824 | 13,117 | |||
| Other assets | 6,168 | 2,025 | |||
| Total assets | 1,614,365 | $ | 1,470,114 | ||
| Liabilities and stockholders’ equity | |||||
| Current liabilities | |||||
| Accounts payable | 17,279 | $ | 10,291 | ||
| Accrued expenses and other current liabilities | 42,447 | 37,692 | |||
| Current portion of debt | 7,029 | 7,029 | |||
| Operating lease liabilities, current | 5,926 | 4,539 | |||
| Total current liabilities | 72,681 | 59,551 | |||
| Debt, net | 656,868 | 659,888 | |||
| Operating lease liabilities, net of current portion | 32,033 | 33,467 | |||
| Other liabilities | 6,387 | 5,849 | |||
| Total liabilities | 767,969 | 758,755 | |||
| Stockholders’ equity | |||||
| Preferred stock | — | — | |||
| Common stock, 0.0001 par value | 39 | 39 | |||
| Additional paid-in capital | 2,222,150 | 2,101,773 | |||
| Accumulated deficit | (1,375,793 | ) | (1,390,453 | ) | |
| Total stockholders’ equity | 846,396 | 711,359 | |||
| Total liabilities and stockholders’ equity | 1,614,365 | $ | 1,470,114 |
All values are in US Dollars.
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 13 |
|---|
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | 2021 | 2020 | 2021 | 2020 | ||||||||
| Revenue | $ | 195,102 | $ | 140,453 | $ | 532,168 | $ | 397,156 | ||||
| Costs and operating expenses: | ||||||||||||
| Cost of revenue, exclusive of depreciation and amortization presented separately below | 11,271 | 7,540 | 32,789 | 20,383 | ||||||||
| Product development and technology | 35,073 | 15,846 | 90,800 | 38,133 | ||||||||
| Sales and marketing | 95,651 | 65,113 | 263,726 | 180,195 | ||||||||
| General and administrative | 35,947 | 108,479 | 119,312 | 120,698 | ||||||||
| Depreciation and amortization | 10,161 | 5,160 | 23,891 | 14,026 | ||||||||
| Total costs and operating expenses | 188,103 | 202,138 | 530,518 | 373,435 | ||||||||
| Operating income (loss) | 6,999 | (61,685 | ) | 1,650 | 23,721 | |||||||
| Other expense, net: | ||||||||||||
| Other expense (income), net | — | 1 | — | (20 | ) | |||||||
| Interest income | (13 | ) | (24 | ) | (42 | ) | (140 | ) | ||||
| Interest expense | 5,928 | 6,264 | 17,739 | 21,697 | ||||||||
| Total other expense, net | 5,915 | 6,241 | 17,697 | 21,537 | ||||||||
| Income (loss) before income taxes | 1,084 | (67,926 | ) | (16,047 | ) | 2,184 | ||||||
| Income tax (expense) benefit | (19,153 | ) | 17,894 | 30,707 | 2,467 | |||||||
| Net (loss) income | $ | (18,069 | ) | $ | (50,032 | ) | $ | 14,660 | $ | 4,651 | ||
| Net (loss) income attributable to common stockholders: | ||||||||||||
| Basic | $ | (18,069 | ) | $ | (50,032 | ) | $ | 14,660 | $ | 3,045 | ||
| Diluted | $ | (18,069 | ) | $ | (50,032 | ) | $ | 14,660 | $ | 3,092 | ||
| (Loss) earnings per share: | ||||||||||||
| Basic | $ | (0.04 | ) | $ | (0.21 | ) | $ | 0.04 | $ | 0.01 | ||
| Diluted | $ | (0.04 | ) | $ | (0.21 | ) | $ | 0.03 | $ | 0.01 | ||
| Weighted average shares used in computing (loss) earnings per share: | ||||||||||||
| Basic | 411,223 | 241,061 | 408,604 | 233,727 | ||||||||
| Diluted | 411,223 | 241,061 | 429,695 | 244,529 | ||||||||
| Stock-based compensation included in costs and operating expenses: | ||||||||||||
| Cost of revenue | $ | 238 | $ | 57 | $ | 540 | $ | 98 | ||||
| Product development and technology | 10,333 | 2,958 | 26,656 | 4,772 | ||||||||
| Sales and marketing | 5,638 | 4,284 | 16,158 | 5,762 | ||||||||
| General and administrative | 23,771 | 99,574 | 83,828 | 100,572 | ||||||||
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 14 | ||||||||||
| --- | --- | --- |
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Nine Months EndedSeptember 30, | ||||||
|---|---|---|---|---|---|---|
| (in thousands) | 2021 | 2020 | ||||
| Cash flows from operating activities | ||||||
| Net income | $ | 14,660 | $ | 4,651 | ||
| Adjustments to reconcile net income to net cash provided by <br>operating activities: | ||||||
| Depreciation and amortization | 23,891 | 14,026 | ||||
| Amortization of debt issuance costs | 2,586 | 2,430 | ||||
| Non-cash operating lease expense | 2,451 | 3,431 | ||||
| Stock-based compensation expense | 127,182 | 111,204 | ||||
| Change in fair value of contingent consideration | — | 901 | ||||
| Deferred income taxes | (33,217 | ) | 2,292 | |||
| Loss on abandonment of operating lease assets | 1,430 | — | ||||
| Changes in operating assets and liabilities, net of effects of business acquisitions | ||||||
| Accounts receivable | (24,380 | ) | (10,928 | ) | ||
| Prepaid expenses and other assets | 5,696 | (31,832 | ) | |||
| Accounts payable | 4,322 | 3,411 | ||||
| Accrued expenses and other current liabilities | 5,311 | 13,763 | ||||
| Operating lease liabilities | (1,501 | ) | 1,641 | |||
| Other liabilities | 538 | 1,501 | ||||
| Net cash provided by operating activities | 128,969 | 116,491 | ||||
| Cash flows from investing activities | ||||||
| Purchase of property and equipment | (3,764 | ) | (15,681) | |||
| Acquisitions, net of cash acquired | (140,268 | ) | (55,793) | |||
| Capitalized software | (21,434 | ) | (10,333) | |||
| Investment in minority equity interest | (4,008 | ) | — | |||
| Net cash used in investing activities | (169,474 | ) | (81,807 | ) | ||
| Cash flows from financing activities | ||||||
| Proceeds from issuance of common stock in initial public offering, <br>net of underwriting discounts and<br>commissions | — | 891,793 | ||||
| Proceeds from private placement | — | 100,000 | ||||
| Proceeds from long-term debt | — | 28,000 | ||||
| Payments on long-term debt | (5,272 | ) | (5,272) | |||
| Payment for contingent consideration | (832 | ) | — | |||
| Payment of debt issuance costs | — | (1,306 | ) | |||
| Payments of initial public offering issuance costs | — | (1,840 | ) | |||
| Proceeds from exercise of stock options | 29,715 | 5,148 | ||||
| Proceeds from early exercise of stock options | — | 667 | ||||
| Employee taxes paid related to net share settlement of equity awards | (42,674 | ) | — | |||
| Net cash (used in) provided by financing activities | (19,063 | ) | 1,017,190 | |||
| Net change in cash, cash equivalents and restricted cash | (59,568 | ) | 1,051,874 | |||
| Cash, cash equivalents and restricted cash | ||||||
| Beginning of period | 971,591 | 26,050 | ||||
| End of period | $ | 912,023 | $ | 1,077,924 | ||
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 15 | ||||
| --- | --- | --- |
Non-GAAP Financial Measures Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Margin, Adjusted Earnings Per Share and Adjusted Operating Income are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and operating expense on our condensed consolidated statements of operations on an adjusted basis. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures”. We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for acquisition related expenses, cash bonuses to vested option holders, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on abandonment and impairment of operating lease assets, charitable stock donation and other income or expense, net, as applicable for the periods presented. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on abandonment and impairment of operating lease assets, charitable stock donation, and as further adjusted for estimated income tax on such adjusted items. Adjusted income tax (expense) benefit was determined by applying an adjusted estimated annual effective income tax rate to interim non-GAAP adjusted income before income taxes and including the tax effect of certain discrete items recognized during the period. Our adjusted estimated annual effective income tax rate is based on our full-year estimate of non-GAAP adjusted income before income taxes. Adjusted income tax (expense) benefit excludes excess tax benefits/deficiencies recognized in connection with stock-based compensation. Adjusted Net Margin is Adjusted Net Income divided by revenue.
Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted, depending on whether the Company has adjusted net loss or adjusted net income, respectively. We also assess our performance by evaluating each cost and operating expense on our condensed consolidated statements of operations on a non-GAAP, or adjusted, basis to arrive at Adjusted Operating Income. The adjustments to these cost and operating expense items include acquisition related expenses, amortization of intangible assets related to acquisitions, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, and as applicable, loss on abandonment and impairment of operating lease assets and charitable stock donation. Adjusted Operating Income is GAAP revenue less non-GAAP operating expenses. We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted EBITDA is also a key measure we use to assess our financial performance and is also used for internal planning and forecasting purposes. In addition, Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings Per Share are frequently used by analysts, investors and other interested parties to evaluate and assess performance. The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.
The following table presents a reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP:
| Three Months Ended | Nine Months EndedSeptember 30, | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (dollars in thousands) | September 30, 2021 | June 30,<br><br><br>2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30,<br><br><br>2020 | March 31, 2020 | 2021 | 2020 | |||||||||||||||||||||||||||
| Net (loss) income | $ | (18,069 | ) | $ | 31,061 | $ | 1,668 | $ | (298,274 | ) | $ | (50,032 | ) | $ | 27,337 | $ | 27,346 | $ | 14,660 | $ | 4,651 | |||||||||||||||
| Adjusted to exclude the following: | ||||||||||||||||||||||||||||||||||||
| Interest income | (13 | ) | (13 | ) | (16 | ) | (20 | ) | (24 | ) | (41 | ) | (75 | ) | (42 | ) | (140 | ) | ||||||||||||||||||
| Interest expense | 5,928 | 5,906 | 5,905 | 6,216 | 6,264 | 6,795 | 8,638 | 17,739 | 21,697 | |||||||||||||||||||||||||||
| Income tax expense (benefit) | 19,153 | (37,305 | ) | (12,555 | ) | (7,360 | ) | (17,894 | ) | 7,661 | 7,766 | (30,707 | ) | (2,467 | ) | |||||||||||||||||||||
| Depreciation and amortization | 10,161 | 8,369 | 5,361 | 4,404 | 5,160 | 4,521 | 4,345 | 23,891 | 14,026 | |||||||||||||||||||||||||||
| Other (income) expense, net | — | — | — | (2 | ) | 1 | (16 | ) | (5 | ) | — | (20 | ) | |||||||||||||||||||||||
| Financing related expenses ^(1)^ | 134 | 58 | 257 | 13 | — | 188 | 1,118 | 449 | 1,306 | |||||||||||||||||||||||||||
| Acquisition related expenses^(2)^ | 1,714 | 3,022 | 3,048 | 3,642 | 2,481 | 780 | 463 | 7,784 | 3,724 | |||||||||||||||||||||||||||
| Stock-based compensation expense ^(3)^ | 39,980 | 40,676 | 46,526 | 286,081 | 106,873 | 2,121 | 2,210 | 127,182 | 111,204 | |||||||||||||||||||||||||||
| Charitable stock donation ^(4)^ | — | — | — | 41,721 | — | — | — | — | — | |||||||||||||||||||||||||||
| Payroll tax expense related to stock-based compensation | 2,150 | 2,016 | 828 | 11,682 | 323 | 22 | 59 | 4,994 | 404 | |||||||||||||||||||||||||||
| Loss on abandonment and impairment of operating lease assets<br>^(5)^ | 650 | 780 | — | 961 | — | — | — | 1,430 | — | |||||||||||||||||||||||||||
| Adjusted EBITDA | $ | 61,788 | $ | 54,570 | $ | 51,022 | $ | 49,064 | $ | 53,152 | $ | 49,368 | $ | 51,865 | $ | 167,380 | $ | 154,385 | ||||||||||||||||||
| Adjusted EBITDA Margin | 31.7 | % | 30.9 | % | 31.8 | % | 32.0 | % | 37.8 | % | 40.0 | % | 38.9 | % | 31.5 | % | 38.9 | % |
(1) Financing related expenses include third party fees related to proposed financings.
(2) Acquisition related expenses include third party fees for actual or planned acquisitions, including related legal, consulting and other expenditures, and as applicable, retention bonuses to employees related to acquisitions and change in fair value of contingent consideration.
(3) Non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number and the valuation of awards.
(4) Non-cash expense related to a donation of 1,075,000 shares of our Class A common stock that was made to a charitable foundation in the fourth quarter of 2020.
(5) Non-cash loss on the abandonment and impairment of operating lease assets related to certain office space that was abandoned or subleased.
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 17 |
|---|
The following tables present a reconciliation of Adjusted Net Income to net (loss) income, the most directly comparable financial measure calculated in accordance with GAAP, and calculation of Adjusted Earnings Per Share:
| Three Months Ended | Nine Months EndedSeptember 30, | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | September 30, 2021 | June 30, 2021 | March 31,2021 | December 31,2020 | September 30,2020 | June 30,2020 | March 31,2020 | 2021 | 2020 | ||||||||||||||||||
| Net (loss) income | $ | (18,069 | ) | $ | 31,061 | $ | 1,668 | $ | (298,274 | ) | $ | (50,032 | ) | $ | 27,337 | $ | 27,346 | $ | 14,660 | $ | 4,651 | ||||||
| Adjusted to exclude the following: | |||||||||||||||||||||||||||
| Amortization of intangibles related to acquisitions | 5,703 | 4,868 | 2,476 | 2,307 | 3,651 | 3,280 | 3,421 | 13,047 | 10,352 | ||||||||||||||||||
| Financing related expenses ^(1)^ | 134 | 58 | 257 | 13 | — | 188 | 1,118 | 449 | 1,306 | ||||||||||||||||||
| Acquisition related expenses^(2)^ | 1,714 | 3,022 | 3,048 | 3,642 | 2,481 | 780 | 463 | 7,784 | 3,724 | ||||||||||||||||||
| Stock-based compensation expense ^(3)^ | 39,980 | 40,676 | 46,526 | 286,081 | 106,873 | 2,121 | 2,210 | 127,182 | 111,204 | ||||||||||||||||||
| Payroll tax expense related to stock-based compensation | 2,150 | 2,016 | 828 | 11,682 | 323 | 22 | 59 | 4,994 | 404 | ||||||||||||||||||
| Charitable stock donation ^(4)^ | — | — | — | 41,721 | — | — | — | — | — | ||||||||||||||||||
| Loss on abandonment and impairment of operating lease assets<br>^(5)^ | 650 | 780 | — | 961 | — | — | — | 1,430 | — | ||||||||||||||||||
| Income tax expense (benefit) on excluded items and adjusting for excess tax benefits/deficiencies on<br>stock-based compensation exercises | 7,388 | (47,410 | ) | (22,961 | ) | (15,919 | ) | (27,661 | ) | (1,438 | ) | (1,439 | ) | (62,983 | ) | (30,538 | ) | ||||||||||
| Adjusted net income | $ | 39,650 | $ | 35,071 | $ | 31,842 | $ | 32,214 | $ | 35,635 | $ | 32,290 | $ | 33,178 | $ | 106,563 | $ | 101,103 | |||||||||
| Less: Adjusted undistributed earnings allocated to convertible preferred stock | — | — | — | — | (11,698 | ) | (11,466 | ) | (11,749 | ) | — | (34,913 | ) | ||||||||||||||
| Adjusted net income attributable to common stockholders - basic | $ | 39,650 | $ | 35,071 | $ | 31,842 | $ | 32,214 | $ | 23,937 | $ | 20,824 | $ | 21,429 | $ | 106,563 | $ | 66,190 | |||||||||
| Add: Adjusted undistributed earnings allocated to holders of common stock | — | — | — | — | 597 | 222 | 206 | — | 1,025 | ||||||||||||||||||
| Adjusted net income attributable to common stockholders - diluted | $ | 39,650 | $ | 35,071 | $ | 31,842 | $ | 32,214 | $ | 24,534 | $ | 21,046 | $ | 21,635 | $ | 106,563 | $ | 67,215 | |||||||||
| Weighted average shares used in computing adjusted earnings per share: | |||||||||||||||||||||||||||
| Weighted average shares - basic | 411,223 | 408,363 | 406,170 | 401,459 | 241,061 | 230,160 | 229,880 | 408,604 | 233,727 | ||||||||||||||||||
| Dilutive impact of stock options, restricted stock awards and restricted stock units | 18,497 | 20,504 | 23,407 | 26,776 | 19,300 | 6,730 | 6,345 | 21,091 | 10,802 | ||||||||||||||||||
| Weighted average shares - diluted | 429,720 | 428,867 | 429,577 | 428,235 | 260,361 | 236,890 | 236,225 | 429,695 | 244,529 | ||||||||||||||||||
| Adjusted earnings per share: | |||||||||||||||||||||||||||
| Basic | $ | 0.10 | $ | 0.09 | $ | 0.08 | $ | 0.08 | $ | 0.10 | $ | 0.09 | $ | 0.09 | $ | 0.26 | $ | 0.28 | |||||||||
| Diluted | $ | 0.09 | $ | 0.08 | $ | 0.07 | $ | 0.08 | $ | 0.09 | $ | 0.09 | $ | 0.09 | $ | 0.25 | $ | 0.27 |
(1) Financing related expenses include third party fees related to proposed financings.
(2) Acquisition related expenses include third party fees for actual or planned acquisitions, including related legal, consulting and other expenditures, and as applicable, retention bonuses to employees related to acquisitions and change in fair value of contingent consideration.
(3) Non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number and the valuation of awards.
(4) Non-cash expense related to a donation of 1,075,000 shares of our Class A common stock that was made to a charitable foundation in the fourth quarter of 2020.
(5) Non-cash loss on the abandonment and impairment of operating lease assets related to certain office space that was abandoned or subleased.
The weighted average number of redeemable convertible preferred stock outstanding during the three and nine months ended September 30, 2021 and 2020 was as follows:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| (in thousands) | 2021 | 2020 | 2021 | 2020 | ||||
| Redeemable convertible preferred stock | — | 117,825 | — | 123,285 | ||||
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 18 | ||||||
| --- | --- | --- |
Each cost and operating expense is adjusted for acquisition related expenses, amortization of intangible assets related to acquisitions, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, and as applicable, loss on abandonment and impairment of operating lease assets and charitable stock donation.
| GAAPThree Months EndedSeptember 30, | AdjustedThree Months EndedSeptember 30, | GAAPNine Months EndedSeptember 30, | AdjustedNine Months EndedSeptember 30, | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (dollars in thousands) | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | ||||||||||||||||
| Cost of revenue | $ | 11,271 | $ | 7,540 | $ | 11,138 | $ | 7,483 | $ | 32,789 | $ | 20,383 | $ | 32,213 | $ | 20,285 | ||||||||
| % of Revenue | 5.8 | % | 5.4 | % | 5.7 | % | 5.3 | % | 6.2 | % | 5.1 | % | 6.1 | % | 5.1 | % | ||||||||
| Product development and technology | $ | 35,073 | $ | 15,846 | $ | 23,156 | $ | 12,512 | $ | 90,800 | $ | 38,133 | $ | 60,179 | $ | 32,207 | ||||||||
| % of Revenue | 18.0 | % | 11.3 | % | 11.9 | % | 8.9 | % | 17.1 | % | 9.6 | % | 11.3 | % | 8.1 | % | ||||||||
| Sales and marketing | $ | 95,651 | $ | 65,113 | $ | 89,286 | $ | 60,817 | $ | 263,726 | $ | 180,195 | $ | 245,918 | $ | 174,421 | ||||||||
| % of Revenue | 49.0 | % | 46.4 | % | 45.8 | % | 43.3 | % | 49.6 | % | 45.4 | % | 46.2 | % | 43.9 | % | ||||||||
| General and administrative | $ | 35,947 | $ | 108,479 | $ | 9,734 | $ | 6,489 | $ | 119,312 | $ | 120,698 | $ | 26,478 | $ | 15,858 | ||||||||
| % of Revenue | 18.4 | % | 77.2 | % | 5.0 | % | 4.6 | % | 22.4 | % | 30.4 | % | 5.0 | % | 4.0 | % | ||||||||
| Depreciation and amortization | $ | 10,161 | $ | 5,160 | $ | 4,458 | $ | 1,509 | $ | 23,891 | $ | 14,026 | $ | 10,844 | $ | 3,674 | ||||||||
| % of Revenue | 5.2 | % | 3.7 | % | 2.3 | % | 1.1 | % | 4.5 | % | 3.5 | % | 2.0 | % | 0.9 | % | ||||||||
| Operating income (loss) | $ | 6,999 | $ | (61,685 | ) | $ | 57,330 | $ | 51,643 | $ | 1,650 | $ | 23,721 | $ | 156,536 | $ | 150,711 | |||||||
| % of Revenue | 3.6 | % | (43.9 | %) | 29.4 | % | 36.8 | % | 0.3 | % | 6.0 | % | 29.4 | % | 37.9 | % | ||||||||
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 19 | ||||||||||||||||||||||
| --- | --- | --- |
The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense measure to its most directly comparable financial measure calculated in accordance with GAAP:
| Three Months Ended<br>September 30, | Nine Months Ended<br>September 30, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands) | 2021 | 2020 | 2021 | 2020 | ||||||||
| Cost of revenue | $ | 11,271 | $ | 7,540 | $ | 32,789 | $ | 20,383 | ||||
| Acquisition related expenses | 123 | — | 46 | — | ||||||||
| Stock-based compensation expense | (238 | ) | (57 | ) | (540 | ) | (98 | ) | ||||
| Payroll tax expense related to stock-based compensation | (18 | ) | — | (82 | ) | — | ||||||
| Adjusted cost of revenue | $ | 11,138 | $ | 7,483 | $ | 32,213 | $ | 20,285 | ||||
| Product development and technology | $ | 35,073 | $ | 15,846 | $ | 90,800 | $ | 38,133 | ||||
| Acquisition related expenses | (560 | ) | (376 | ) | (1,506 | ) | (1,154 | ) | ||||
| Stock-based compensation expense | (10,333 | ) | (2,958 | ) | (26,656 | ) | (4,772 | ) | ||||
| Payroll tax expense related to stock-based compensation | (1,024 | ) | — | (2,459 | ) | — | ||||||
| Adjusted product development and technology | $ | 23,156 | $ | 12,512 | $ | 60,179 | $ | 32,207 | ||||
| Sales and marketing | $ | 95,651 | $ | 65,113 | $ | 263,726 | $ | 180,195 | ||||
| Acquisition related expenses | (292 | ) | (12 | ) | (773 | ) | (12 | ) | ||||
| Stock-based compensation expense | (5,638 | ) | (4,284 | ) | (16,158 | ) | (5,762 | ) | ||||
| Payroll tax expense related to stock-based compensation | (435 | ) | — | (877 | ) | — | ||||||
| Adjusted sales and marketing | $ | 89,286 | $ | 60,817 | $ | 245,918 | $ | 174,421 | ||||
| General and administrative | $ | 35,947 | $ | 108,479 | $ | 119,312 | $ | 120,698 | ||||
| Financing related expenses | (134 | ) | — | (449 | ) | (1,306 | ) | |||||
| Acquisition related expenses | (985 | ) | (2,093 | ) | (5,551 | ) | (2,558 | ) | ||||
| Stock-based compensation expense | (23,771 | ) | (99,574 | ) | (83,828 | ) | (100,572 | ) | ||||
| Payroll tax expense related to stock-based compensation | (673 | ) | (323 | ) | (1,576 | ) | (404 | ) | ||||
| Loss on abandonment of operating lease assets ^(1)^ | (650 | ) | — | (1,430 | ) | — | ||||||
| Adjusted general and administrative | $ | 9,734 | $ | 6,489 | $ | 26,478 | $ | 15,858 | ||||
| Depreciation and amortization | $ | 10,161 | $ | 5,160 | $ | 23,891 | $ | 14,026 | ||||
| Amortization of intangibles related to acquisitions | (5,703 | ) | (3,651 | ) | (13,047 | ) | (10,352 | ) | ||||
| Adjusted depreciation and amortization | $ | 4,458 | $ | 1,509 | $ | 10,844 | $ | 3,674 | ||||
| Operating income (loss) | $ | 6,999 | $ | (61,685 | ) | $ | 1,650 | $ | 23,721 | |||
| Amortization of intangibles related to acquisitions | 5,703 | 3,651 | 13,047 | 10,352 | ||||||||
| Financing related expenses | 134 | — | 449 | 1,306 | ||||||||
| Acquisition related expenses | 1,714 | 2,481 | 7,784 | 3,724 | ||||||||
| Stock-based compensation expense | 39,980 | 106,873 | 127,182 | 111,204 | ||||||||
| Payroll tax expense related to stock-based compensation | 2,150 | 323 | 4,994 | 404 | ||||||||
| Loss on abandonment of operating lease assets ^(1)^ | 650 | — | 1,430 | — | ||||||||
| Adjusted operating income | $ | 57,330 | $ | 51,643 | $ | 156,536 | $ | 150,711 |
(1) Non-cash loss with respect to certain leased office space that was abandoned in the three and nine months ended September 30, 2021. There were no impairment losses in the three and nine months ended September 30, 2021 and 2020.
| GoodRx Holdings, Inc. | Q3 2021 Letter to Shareholders | 20 |
|---|